TASER International, Inc. (NASDAQ:TASR), announced that Bret Taylor will be joining its Board of Directors. Mr. Taylor was the co-creator of Google Maps, CEO of Friendfeed, CTO of Facebook, and is now CEO of Quip. He brings extensive technology experience to the Company as TASER and its business unit EVIDENCE.com, looks to accelerate growth in the wearable camera and cloud computing space for law enforcement. Mr. Taylor will be filling a board seat vacated by Dr. Matthew McBrady, who is retiring from the Board due to a new job in the financial industry which precludes him from serving on the boards of public companies. TASER International, Inc. (NASDAQ:TASR), net profit margin is 12.80% and weekly performance is 9.85%. On last trading day company shares ended up $14.28. Analysts mean target price for the company is $17.50. TASER International, Inc. (NASDAQ:TASR), distance from 50-day simple moving average (SMA50) is -6.95%.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), was a big mover last session, as the company saw its shares rise nearly 8% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $1.02 to $1.21 in the past one-month time frame, showed a pick-up yesterday at $1.10. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), advanced 12.73% in last trading session and ended the day on $1.24. AVEO, return on assets is -50.60%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), quarterly performance is -32.97%.
On May 30, 2014, CTI BioPharma Corp (NASDAQ:CTIC), says it will change its corporate name to CTI BioPharma Corp effective May, 30, 2014 . The company’s common stock will continue to trade under its current ticker symbol: “CTIC.” CTI BioPharma Corp (NASDAQ:CTIC), shares moved up 4.97% in last trading session and was closed at $3.17, while trading in range of $2.97 – 3.22. CTI BioPharma Corp (NASDAQ:CTIC), year to date (YTD) performance is 65.97%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s shares gained 1.11% to $16.44. The company on June 2 reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX), ended the last trading day at $17.26. Company weekly volatility is calculated as 9.58% and price to cash ratio as 5.62. Celldex Therapeutics, Inc. (NASDAQ:CLDX), showed a positive weekly performance of 30.56%.
On June 05, 2014, Shares in Molycorp Inc. finished 11.60% higher at $2.79. A total of 8.48 million shares were traded, which was above its three months average volume of 5.04 million shares. The stock moved between $2.52 and $2.83 during the session. Although, Molycorp Inc.’s stock has advanced 0.72% in the previous three trading sessions, it has declined 41.39% in the last one month months and 50.36% on YTD basis. Molycorp Inc (NYSE:MCP), net profit margin is -90.00% and weekly performance is 12.00%. On last trading day company shares ended up $2.80. Analysts mean target price for the company is $4.10. Molycorp Inc (NYSE:MCP), distance from 50-day simple moving average (SMA50) is -28.74%.